NCT06154174

Brief Summary

The goal of this clinical trial is to test adding choline to ready-to-use therapeutic food (RUTF) in children with severe acute malnutrition (SAM) in Malawi. The main question it aims to answer is: \- Will the addition of a 500mg daily dose of choline to RUTF during treatment for SAM improve cognitive development among 6-59-month-old Malawian children compared with standard RUTF without added choline?

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,500

participants targeted

Target at P75+ for not_applicable

Timeline
4mo left

Started Dec 2023

Typical duration for not_applicable

Geographic Reach
1 country

10 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress87%
Dec 2023Nov 2026

First Submitted

Initial submission to the registry

October 18, 2023

Completed
2 months until next milestone

First Posted

Study publicly available on registry

December 4, 2023

Completed
1 day until next milestone

Study Start

First participant enrolled

December 5, 2023

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2026

Last Updated

March 17, 2026

Status Verified

March 1, 2026

Enrollment Period

2.9 years

First QC Date

October 18, 2023

Last Update Submit

March 16, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Malawi Developmental Assessment Tool global z-score

    Age-standardized score, -6 to +6, higher scores are better

    6 months after SAM outcome

Secondary Outcomes (23)

  • Malawi Developmental Assessment Tool gross motor sub-domain z-score

    6 months after SAM outcome

  • Malawi Developmental Assessment Tool fine motor sub-domain z-score

    6 months after SAM outcome

  • Malawi Developmental Assessment Tool language sub-domain z-score

    6 months after SAM outcome

  • Malawi Developmental Assessment Tool social sub-domain z-score

    6 months after SAM outcome

  • Malawi Developmental Assessment Tool global z-score

    Within 1 month of SAM outcome

  • +18 more secondary outcomes

Other Outcomes (2)

  • MDAT global z-score by age

    6-month post-outcome MDAT visit

  • MDAT global z-score by SAM outcome status

    6-month post-outcome MDAT visit

Study Arms (2)

C-RUTF (Ready-to-Use Therapeutic Food with added choline)

EXPERIMENTAL

A daily dose of 500mg choline will be added to RUTF. 2 sachets (daily dose) of RUTF will provide approximately 1000 Kcal, 14g of protein, 28g of fat, and 1 RDA of 14 micronutrients.

Dietary Supplement: C-RUTF (Ready-to-Use Therapeutic Food with added choline)Drug: Amoxicillin

S-RUTF (Ready-to-Use Therapeutic Food without added choline)

ACTIVE COMPARATOR

A daily dose of 5mg choline will be added to RUTF for masking. 2 sachets (daily dose) of RUTF will provide approximately 1000 Kcal, 14g of protein, 28g of fat, and 1 RDA or 14 micronutrients.

Dietary Supplement: S-RUTF (Ready-to-Use Therapeutic Food without added choline)Drug: Amoxicillin

Interventions

Oral amoxicillin tablets twice per day for 7 days dosed based on weight

C-RUTF (Ready-to-Use Therapeutic Food with added choline)S-RUTF (Ready-to-Use Therapeutic Food without added choline)

Standard peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications

S-RUTF (Ready-to-Use Therapeutic Food without added choline)

Choline added to peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications

C-RUTF (Ready-to-Use Therapeutic Food with added choline)

Eligibility Criteria

Age6 Months - 59 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • months of age
  • mid-upper arm circumference \< 11.5 cm and/or weight-for-length z-score \< -3 and/or presence of bilateral pedal pitting edema
  • willingness to comply with all study procedures and availability for the duration of the study, including no plan to move from the catchment area of a participating clinic

You may not qualify if:

  • features of complicated SAM: inability to tolerate a 30g test dose of RUTF, breathing difficulties, mental status changes, sepsis, or physician/nursing clinical assessment that the child needs immediate hospitalization
  • participation in a separate feeding program within the past month
  • known allergy to study food ingredient (peanut, milk, fish)
  • intention to move away from catchment area within 9 months
  • developmental delay
  • presence of a chronic severe medical condition (other than TB and HIV), such as congenital heart disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (10)

Makhwira

Makhwira, Chikwawa, Malawi

RECRUITING

Mitondo

Mitondo, Chikwawa, Malawi

RECRUITING

Nkhate

Nkhate, Chikwawa, Malawi

RECRUITING

Chipolonga

Chipolonga, Machinga, Malawi

RECRUITING

Chikonde

Chikonde, Mulanje, Malawi

RECRUITING

Mbiza

Mbiza, Mulanje, Malawi

RECRUITING

Milonde

Milonde, Mulanje, Malawi

RECRUITING

Muloza

Muloza, Mulanje, Malawi

RECRUITING

Namasalima

Namasalima, Mulanje, Malawi

RECRUITING

Naphimba

Naphimba, Mulanje, Malawi

RECRUITING

MeSH Terms

Conditions

Severe Acute MalnutritionCognitive DysfunctionCachexiaKwashiorkor

Interventions

Amoxicillin

Condition Hierarchy (Ancestors)

MalnutritionNutrition DisordersNutritional and Metabolic DiseasesCognition DisordersNeurocognitive DisordersMental DisordersWeight LossBody Weight ChangesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsThinness

Intervention Hierarchy (Ancestors)

AmpicillinPenicillin GPenicillinsbeta-LactamsLactamsAmidesOrganic ChemicalsSulfur CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • Mark J Manary, MD

    Washington University School of Medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mark J Manary, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
The intervention and control RUTFs will be packaged in identical opaque sachets aside from colored stickers which will indicate randomization group. The intervention and control RUTFs will be identical in appearance, consistency, and smell. Efforts have been made to mask possible taste differences resulting from choline, including by the addition of a small amount (5mg) of choline to the control food. Participant masking cannot be guaranteed, however.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 18, 2023

First Posted

December 4, 2023

Study Start

December 5, 2023

Primary Completion (Estimated)

November 1, 2026

Study Completion (Estimated)

November 1, 2026

Last Updated

March 17, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will share

All collected, de-identified individual patient data

Shared Documents
STUDY PROTOCOL, SAP, ICF, ANALYTIC CODE
Time Frame
Within 12 months of primary publication

Locations